摘要
目的:探讨依达拉奉联合奥拉西坦治疗大面积脑梗死的疗效及对患者神经功能的影响。方法:选取2015年1月—2017年6月广州市从化区南方医科大学第五附属医院收治的大面积脑梗死患者80例,按照入院顺序分组,单号为观察组,双号为对照组,每组40例。对照组患者给予常规治疗联合奥拉西坦,观察组患者在对照组基础上加用依达拉奉。观察两组患者治疗前后的中国卒中量表评分、美国国立卫生研究院卒中量表评分、临床疗效及不良反应发生情况。结果:治疗后,观察组患者中国卒中量表评分、美国国立卫生研究院卒中量表评分明显低于对照组,差异均有统计学意义(P<0.05);观察组患者的总有效率为95.00%(38/40),明显高于对照组的77.50%(31/40),差异有统计学意义(P<0.05);观察组、对照组患者不良反应发生率分别为7.50%(3/40)、5.00%(2/40),差异无统计学意义(P>0.05)。结论:依达拉奉联合奥拉西坦治疗大面积脑梗死的疗效显著,可有效改善患者神经功能。
OBJECTIVE: To probe into the efficacy of edaravone combined with oxiracetam in treatment of massive cerebral infarction and its effects on neurological function. METHODS: 80 patients with massive cerebral infarction admitted into the Fifth Affiliated Hospital of Southern Medical University from Jan. 2015 to Jun. 2017 were selected and divided into observation group( odd numbers) and control group( even numbers) via admission sequence,with 40 cases in each. The control group was given conventional therapy combined with oxiracetam,the observation group was treated with edaravone based on the control group. Scores of CSS and NIHSS,clinical efficacy and incidences of adverse drug reactions of two groups were observed. RESULTS: After treatment,the scores of CSS and NIHSS of observation groups were significantly lower than those of the control group,with statistically significant differences( P〈0. 05); the total effective rate of observation group was 95. 00%( 38/40),which was significantly higher than that of the control group( 77. 50%,31/40),with statistically significant difference( P〈0. 05); the incidences of adverse drug reactions of observation group and control group were respectively 7. 50%( 3/40) and 5. 00%( 2/40),with no statistically significant difference( P〉0. 05). CONCLUSIONS: The efficacy of edaravone combined with oxiracetam in treatment of massive cerebral infarction is remarkable, which can significantly improve patients 'neurological function.
出处
《中国医院用药评价与分析》
2018年第2期185-186,189,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
依达拉奉
奥拉西坦
大面积脑梗死
疗效
神经功能
Edaravone
Oxiracetam
Massive cerebral infarction
Efficacy
Neurological function